Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics Inc (TARA) is a clinical-stage biotechnology company developing transformative therapies for cancer and rare diseases. This page provides investors and industry observers with timely updates on clinical trials, regulatory milestones, and corporate developments.
Access comprehensive coverage of TARA's investigational cell therapy TARA-002 for lymphatic malformations and IV Choline Chloride research. Our news collection features press releases, peer-reviewed data publications, and strategic partnership announcements.
Key updates include progress reports on:
• Clinical trial phases
• FDA designations
• Scientific conference presentations
• Intellectual property developments
Bookmark this page for centralized access to Protara's latest advancements in immunopotentiator therapies and metabolic replacement solutions. Monitor critical updates affecting the company's position in the oncology and rare disease treatment landscapes.
Protara Therapeutics (Nasdaq: TARA) has appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer. Dr. Nicacio brings nearly 20 years of experience in oncology, drug development, regulatory and commercial sectors.
Prior to joining Protara, Dr. Nicacio served as Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics. He previously held the position of Vice President, Clinical Development at Seagen, where he managed development programs across multiple cancer types. His experience includes roles at AstraZeneca, Flatiron Health, Sanofi, and YM Biosciences.
The company is preparing to present interim data from the ADVANCED-2 clinical trial of TARA-002 in patients with non-muscle invasive bladder cancer later this month. Dr. Nicacio will contribute to Protara's mission of developing transformative therapies for cancer and rare diseases.
Protara Therapeutics (Nasdaq: TARA) announced upcoming presentations of interim analysis from their Phase 2 ADVANCED-2 trial of TARA-002 at the American Urological Association Annual Meeting in Las Vegas (April 26-29, 2025). The trial focuses on treating non-muscle invasive bladder cancer (NMIBC) patients.
The ADVANCED-2 trial (NCT05951179) is an open-label study evaluating intravesical TARA-002 in two patient groups: BCG-unresponsive (n≈100) and BCG-Naïve (n=30) with carcinoma in situ (CIS). The BCG-Unresponsive cohort is designed to be registrational in alignment with FDA's 2024 guidance.
Updated safety and efficacy data, including 12-month evaluation timepoint results, will be presented during an interactive poster session. The event will feature two presentations and a panel discussion with leading urologists and researchers.
Protara Therapeutics (Nasdaq: TARA) has announced an encore presentation of their THRIVE-1 study results at the ASPEN 2025 Nutrition Science & Practice Conference. The study revealed that 78% of patients dependent on parenteral support (PS) were choline deficient, with 63% of these patients showing liver dysfunction.
The company is developing intravenous (IV) Choline Chloride as a treatment for patients who cannot receive choline through oral or enteral nutrition. The treatment has received Fast Track designation from the FDA. Protara plans to initiate THRIVE-3, a registrational Phase 2b/3 trial, in the first half of 2025, which will include an 8-week dose confirmation phase with 24 patients, followed by a 24-week randomized, placebo-controlled phase with 100 patients.
Protara Therapeutics (NASDAQ: TARA) reported Q4 and full year 2024 results, highlighting significant pipeline progress. The company reported positive six-month data from the ADVANCED-2 trial of TARA-002 in NMIBC patients, showing a 72% complete response rate at six months and a favorable safety profile.
Financial highlights include $170.3 million in cash and equivalents as of December 31, 2024, including proceeds from a $100 million public offering, expected to fund operations into 2027. Q4 net loss was $12.8 million ($0.48 per share), with full-year 2024 net loss at $44.6 million ($2.17 per share).
Key upcoming milestones include: initial 12-month data from ADVANCED-2 trial by mid-2025, first patient dosing in THRIVE-3 registrational trial in 1H 2025, and an interim update from STARBORN-1 trial in pediatric LMs by end of 1H 2025.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for March 5, 2025, at 9:50 am ET in Boston.
Interested parties can access a live webcast of the presentation through the Events and Presentations section on Protara's investor relations website at https://ir.protaratx.com. The presentation recording will be available for a time after the event.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a virtual fireside chat scheduled for Wednesday, February 12, 2025, at 12:40 pm ET.
Interested parties can access a live webcast of the presentation through the Events and Presentations section on Protara's investor relations website at https://ir.protaratx.com. The presentation recording will be available for a time following the event.
Protara Therapeutics highlights recent updates and anticipated milestones for 2025. The company reported positive six-month data from the ADVANCED-2 trial of TARA-002 in NMIBC patients, showing a 72% complete response (CR) rate at six months and a favorable safety profile. Data from 12-month evaluable patients is expected mid-2025, with futility analysis results by the end of 2025.
Protara completed a $100 million public offering, extending its financial runway into 2027. The THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support is set to begin in the first half of 2025. Initial results from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients are expected by the end of the first half of 2025.
The company remains focused on developing therapies for cancer and rare diseases, with ongoing efforts in combination therapies and regulatory alignments for future trials.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing transformative therapies for cancer and rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a presentation on Thursday, January 16, 2025, at 7:30 am PT in San Francisco.
The presentation will be accessible through a live webcast on the Events and Presentations section of Protara's investor relations website at https://ir.protaratx.com. Interested parties who cannot attend in person can view the presentation online, and a recording will be available for a time afterward.
Protara Therapeutics (Nasdaq: TARA) has completed its public offering, raising $100 million in gross proceeds. The offering included 13,690,000 common stock shares at $6.25 per share and pre-funded warrants for 2,325,372 shares at $6.249 each. Underwriters received a 30-day option to purchase up to 2,402,305 additional shares. The company plans to use the proceeds to fund the clinical development of TARA-002 and other clinical programs, along with working capital and general corporate purposes. The offering was managed by TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., and Scotiabank as joint book-running managers.
Protara Therapeutics (Nasdaq: TARA) has announced the pricing of its $100 million public offering, consisting of 13,690,000 common stock shares at $6.25 per share and 2,325,372 pre-funded warrants at $6.249 each. The company has granted underwriters a 30-day option to purchase up to 2,402,305 additional shares. The offering is expected to close on December 11, 2024.
The net proceeds will fund the clinical development of TARA-002 and other clinical programs, along with working capital and general corporate purposes. TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., and Scotiabank are serving as joint book-running managers for the offering.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
